ERBB2 and adenocarcinoma: In line with previous observations2,3,9–11,18,28, this analysis showed that both adenocarcinomas and squamous cell carcinomas exhibited upregulation of pathways controlling cell differentiation, adhesion and immune responses, along with higher expression of ERBB2 and TP63 (Fig. 2b, Supplementary Fig. 8a, Supplementary Data 13–14, Q < 0.05, Methods section).